(Poly)phenols in Inflammatory Bowel Disease and Irritable Bowel Syndrome: A Review

• Published in: Molecules (Basel, Switzerland) Switzerland), 2021-03, Vol.26 (7), p.1843
• Main Authors: Hagan, Marilyn, Hayee, Bu' Hussain, Rodriguez-Mateos, Ana
• Format: Article
• Language: English
• Subjects: (poly)phenols; Abdomen; Constipation; Crohn’s disease; Diarrhea; Diet; Endoscopy; Evidence-Based Medicine; Flavonoids; Humans; Inflammation; Inflammatory bowel disease; Inflammatory bowel diseases; Inflammatory Bowel Diseases - drug therapy; Inflammatory Bowel Diseases - metabolism; Inflammatory Bowel Diseases - pathology; inflammatory bowels disease (IBD); Intestinal Mucosa - metabolism; Intestinal Mucosa - pathology; Intestine; Irritable bowel syndrome; irritable bowel syndrome (IBS); Irritable Bowel Syndrome - drug therapy; Irritable Bowel Syndrome - metabolism; Irritable Bowel Syndrome - pathology; Lifestyles; Olive oil; Oxidative stress; Oxidative Stress - drug effects; Pathogenesis; Permeability; Phenols; Polyphenols - therapeutic use; Quality of life; Review; Tea; ulcerative colitis
• ISSN: 1420-3049; 1420-3049
• DOI: 10.3390/molecules26071843

(Poly)phenols (PPs) may have a therapeutic benefit in gastrointestinal (GI) disorders, such as irritable bowel syndrome (IBS) or inflammatory bowel disease (IBD). The aim of this review is to summarise the evidence-base in this regard. Observational evidence does not give a clear indication that PP intake has a preventative role for IBD or IBS, while interventional studies suggest these compounds may confer symptomatic and health-related quality of life improvements in known patients. There are inconsistent results for effects on markers of inflammation, but there are promising reports of endoscopic improvement. Work on the effects of PPs on intestinal permeability and oxidative stress is limited and therefore conclusions cannot be formed. Future work on the use of PPs in IBD and IBS will strengthen the understanding of clinical and mechanistic effects.